Evidence map›Paper›PMID 41561935›Full record

ReviewFrontiers in medicine2025

Hotspot gene mutations and treatment response in myelodysplastic syndromes (MDS): predictive biomarkers and targeted strategies.

Rui Zhang, Wei Kou, Tao Wu, Rui Zhou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rui Zhang *Department of Hematology, Center for Hematologic Diseases of Chinese PLA, The 940th Hospital of Joint Logistics Support force of Chinese People's Liberation Army (Lanzhou Military Command General Hospital), Lanzhou, Gansu, China.
Wei Kou *Medical Department, Northwest Minzu University, Lanzhou, Gansu, China.
Tao WuDepartment of Hematology, Center for Hematologic Diseases of Chinese PLA, The 940th Hospital of Joint Logistics Support force of Chinese People's Liberation Army (Lanzhou Military Command General Hospital), Lanzhou, Gansu, China.
Rui Zhou *Department of Hematology, Center for Hematologic Diseases of Chinese PLA, The 940th Hospital of Joint Logistics Support force of Chinese People's Liberation Army (Lanzhou Military Command General Hospital), Lanzhou, Gansu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by cytopenia and a high risk of transformation to acute myeloid leukemia. In recent years, next-generation sequencing (NGS) has revealed common hotspot gene mutations in MDS, which are not only involved in disease progression, but also affect the responsiveness of different therapeutic strategies. Current research has revealed that

Indexed as

chemotherapyhypomethylating agentsmutationmyelodysplastic syndromestargeted therapy

Identifiers

PMID41561935
PMCPMC12812748

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.